The DOI matches its Crossref record.
Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
Open accessAbstract
BACKGROUND: Alopecia areata (AA) is an autoimmune disease resulting in hair loss with devastating psychosocial consequences. Despite its high prevalence, there are no FDA-approved treatments for AA. Prior studies have identified a prominent interferon signature in AA, which signals through JAK molecules. METHODS: A patient with AA was enrolled in a clinical trial to examine the efficacy of baricitinib, a JAK1/2 inhibitor, to treat concomitant CANDLE syndrome. In vivo, preclinical studies were conducted using the C3H/HeJ AA mouse model to assess the mechanism of clinical improvement by baricitinib. FINDINGS: The patient exhibited a striking improvement of his AA on baricitinib over several months. In vivo studies using the C3H/HeJ mouse model demonstrated a strong correlation between resolution of the interferon signature and clinical improvement during baricitinib treatment. INTERPRETATION: Baricitinib may be an effective treatment for AA and warrants further investigation in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206
Pratt, C. H., King, L. E., Messenger, A. G., Christiano, A. M., & Sundberg, J. P. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.11 · Cited by 787
Self-citationType I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Schwartz, D. M., Bonelli, M., Gadina, M., & O'Shea, J. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.167 · Cited by 648
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0736-y · Cited by 590
Metadata
- Authors
- Jabbari, A., Dai, Z., Xing, L., Cerise, J. E., Ramot, Y., Berkun, Y., Sanchez, G. A. M., Goldbach-Mansky, R., Christiano, A. M., Clynes, R., & Zlotogorski, A.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 2
- Issue
- 4
- Pages
- 351-355
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2105110037
- Cited by
- 233
- References
- 0
- FWCI
- 36.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. https://app.cochat.ai/papers/10.1016/j.ebiom.2015.02.015
- The paper
- Jabbari, A., Dai, Z., Xing, L., Cerise, J. E., Ramot, Y., Berkun, Y., Sanchez, G. A. M., Goldbach-Mansky, R., Christiano, A. M., Clynes, R., & Zlotogorski, A. (2015). Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. https://doi.org/10.1016/j.ebiom.2015.02.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.